A pre-clinical study looking to compare three combination regimens in colorectal, breast, and melanoma tumor mouse models demonstrated that administering anti-PD-L1 concurrently with RT achieved long-term tumor control rather than when it was administered 7 days post-RT. The gene discussed is CD274; the disease is neoplasm.